FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308687030> ?p ?o ?g. }

• W4308687030 abstract "Abstract STUDY QUESTION How should ART/preimplantation genetic testing (PGT) centres manage the detection of chromosomal mosaicism following PGT? SUMMARY ANSWER Thirty good practice recommendations were formulated that can be used by ART/PGT centres as a basis for their own policy with regards to the management of ‘mosaic’ embryos. WHAT IS KNOWN ALREADY The use of comprehensive chromosome screening technologies has provided a variety of data on the incidence of chromosomal mosaicism at the preimplantation stage of development and evidence is accumulating that clarifies the clinical outcomes after transfer of embryos with putative mosaic results, with regards to implantation, miscarriage and live birth rates, and neonatal outcomes. STUDY DESIGN, SIZE, DURATION This document was developed according to a predefined methodology for ESHRE good practice recommendations. Recommendations are supported by data from the literature, a large survey evaluating current practice and published guidance documents. The literature search was performed using PubMed and focused on studies published between 2010 and 2022. The survey was performed through a web-based questionnaire distributed to members of the ESHRE special interest groups (SIG) Reproductive Genetics and Embryology, and the ESHRE PGT Consortium members. It included questions on ART and PGT, reporting, embryo transfer policy and follow-up of transfers. The final dataset represents 239 centres. PARTICIPANTS/MATERIALS, SETTING, METHODS The working group (WG) included 16 members with expertise on the ART/PGT process and chromosomal mosaicism. The recommendations for clinical practice were formulated based on the expert opinion of the WG, while taking into consideration the published data and results of the survey. MAIN RESULTS AND THE ROLE OF CHANCE Eighty percent of centres that biopsy three or more cells report mosaicism, even though only 66.9% of all centres have validated their technology and only 61.8% of these have validated specifically for the calling of chromosomal mosaicism. The criteria for designating mosaicism, reporting and transfer policies vary significantly across the centres replying to the survey. The WG formulated recommendations on how to manage the detection of chromosomal mosaicism in clinical practice, considering validation, risk assessment, designating and reporting mosaicism, embryo transfer policies, prenatal testing and follow-up. Guidance is also provided on the essential elements that should constitute the consent forms and the genetic report, and that should be covered in genetic counselling. As there are several unknowns in chromosomal mosaicism, it is recommended that PGT centres monitor emerging data on the topic and adapt or refine their policy whenever new insights are available from evidence. LIMITATIONS, REASONS FOR CAUTION Rather than providing instant standardized advice, the recommendations should help ART/PGT centres in developing their own policy towards the management of putative mosaic embryos in clinical practice. WIDER IMPLICATIONS OF THE FINDINGS This document will help facilitate a more knowledge-based approach for dealing with chromosomal mosaicism in different centres. In addition to recommendations for clinical practice, recommendations for future research were formulated. Following up on these will direct research towards existing research gaps with direct translation to clinical practice. Emerging data will help in improving guidance, and a more evidence-based approach of managing chromosomal mosaicism. STUDY FUNDING/COMPETING INTEREST(S) The WG received technical support from ESHRE. M.D.R. participated in the EQA special advisory group, outside the submitted work, and is the chair of the PGT WG of the Belgian society for human genetics. D.W. declared receiving salary from Juno Genetics, UK. A.C. is an employee of Igenomix, Italy and C.R. is an employee of Igenomix, Spain. C.S. received a research grant from FWO, Belgium, not related to the submitted work. I.S. declared being a Co-founder of IVFvision Ltd, UK. J.R.V. declared patents related to ‘Methods for haplotyping single-cells’ and ‘Haplotyping and copy number typing using polymorphic variant allelic frequencies’, and being a board member of Preimplantation Genetic Diagnosis International Society (PGDIS) and International Society for Prenatal Diagnosis (ISPD). K.S. reported being Chair-elect of ESHRE. The other authors had nothing to disclose. DISCLAIMER This Good Practice Recommendations (GPR) document represents the views of ESHRE, which are the result of consensus between the relevant ESHRE stakeholders and are based on the scientific evidence available at the time of preparation. ESHRE GPRs should be used for information and educational purposes. They should not be interpreted as setting a standard of care or be deemed inclusive of all proper methods of care, or be exclusive of other methods of care reasonably directed to obtaining the same results. They do not replace the need for application of clinical judgement to each individual presentation, or variations based on locality and facility type. Furthermore, ESHRE GPRs do not constitute or imply the endorsement, or favouring, of any of the included technologies by ESHRE." @default.
• W4308687030 created "2022-11-14" @default.
• W4308687030 creator A5002249027 @default.
• W4308687030 creator A5012839649 @default.
• W4308687030 creator A5019981364 @default.
• W4308687030 creator A5030381344 @default.
• W4308687030 creator A5031548295 @default.
• W4308687030 creator A5044268931 @default.
• W4308687030 creator A5047282667 @default.
• W4308687030 creator A5051476729 @default.
• W4308687030 creator A5057688316 @default.
• W4308687030 creator A5067423949 @default.
• W4308687030 creator A5070641573 @default.
• W4308687030 creator A5072520881 @default.
• W4308687030 creator A5072634770 @default.
• W4308687030 creator A5079772317 @default.
• W4308687030 creator A5082993642 @default.
• W4308687030 creator A5085642193 @default.
• W4308687030 date "2022-01-01" @default.
• W4308687030 modified "2023-10-14" @default.
• W4308687030 title "ESHRE survey results and good practice recommendations on managing chromosomal mosaicism" @default.
• W4308687030 cites W2160952541 @default.
• W4308687030 cites W2177179199 @default.
• W4308687030 cites W2322017433 @default.
• W4308687030 cites W2520737352 @default.
• W4308687030 cites W2571353615 @default.
• W4308687030 cites W2605353647 @default.
• W4308687030 cites W2609225490 @default.
• W4308687030 cites W2741632770 @default.
• W4308687030 cites W2750712999 @default.
• W4308687030 cites W2792185025 @default.
• W4308687030 cites W2803285616 @default.
• W4308687030 cites W2896880577 @default.
• W4308687030 cites W2898113032 @default.
• W4308687030 cites W2900375249 @default.
• W4308687030 cites W2913364560 @default.
• W4308687030 cites W2921078712 @default.
• W4308687030 cites W2949886256 @default.
• W4308687030 cites W2967194441 @default.
• W4308687030 cites W2967759367 @default.
• W4308687030 cites W3001629061 @default.
• W4308687030 cites W3004848573 @default.
• W4308687030 cites W3008304880 @default.
• W4308687030 cites W3011729098 @default.
• W4308687030 cites W3020279152 @default.
• W4308687030 cites W3029117713 @default.
• W4308687030 cites W3029961221 @default.
• W4308687030 cites W3030030551 @default.
• W4308687030 cites W3030565573 @default.
• W4308687030 cites W3031000105 @default.
• W4308687030 cites W3032037546 @default.
• W4308687030 cites W3047972299 @default.
• W4308687030 cites W3080181368 @default.
• W4308687030 cites W3080742954 @default.
• W4308687030 cites W3086648557 @default.
• W4308687030 cites W3091024696 @default.
• W4308687030 cites W3135047559 @default.
• W4308687030 cites W3137127498 @default.
• W4308687030 cites W3138366950 @default.
• W4308687030 cites W3139736334 @default.
• W4308687030 cites W3155894884 @default.
• W4308687030 cites W3184184652 @default.
• W4308687030 cites W3196771187 @default.
• W4308687030 cites W3203250742 @default.
• W4308687030 cites W3211521171 @default.
• W4308687030 cites W3214571675 @default.
• W4308687030 cites W4205273274 @default.
• W4308687030 cites W4221030726 @default.
• W4308687030 cites W4225716753 @default.
• W4308687030 cites W4229450558 @default.
• W4308687030 cites W4241156704 @default.
• W4308687030 doi "https://doi.org/10.1093/hropen/hoac044" @default.
• W4308687030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36349144" @default.
• W4308687030 hasPublicationYear "2022" @default.
• W4308687030 type Work @default.
• W4308687030 citedByCount "10" @default.
• W4308687030 countsByYear W43086870302023 @default.
• W4308687030 crossrefType "journal-article" @default.
• W4308687030 hasAuthorship W4308687030A5002249027 @default.
• W4308687030 hasAuthorship W4308687030A5012839649 @default.
• W4308687030 hasAuthorship W4308687030A5019981364 @default.
• W4308687030 hasAuthorship W4308687030A5030381344 @default.
• W4308687030 hasAuthorship W4308687030A5031548295 @default.
• W4308687030 hasAuthorship W4308687030A5044268931 @default.
• W4308687030 hasAuthorship W4308687030A5047282667 @default.
• W4308687030 hasAuthorship W4308687030A5051476729 @default.
• W4308687030 hasAuthorship W4308687030A5057688316 @default.
• W4308687030 hasAuthorship W4308687030A5067423949 @default.
• W4308687030 hasAuthorship W4308687030A5070641573 @default.
• W4308687030 hasAuthorship W4308687030A5072520881 @default.
• W4308687030 hasAuthorship W4308687030A5072634770 @default.
• W4308687030 hasAuthorship W4308687030A5079772317 @default.
• W4308687030 hasAuthorship W4308687030A5082993642 @default.
• W4308687030 hasAuthorship W4308687030A5085642193 @default.
• W4308687030 hasBestOaLocation W43086870301 @default.
• W4308687030 hasConcept C15744967 @default.
• W4308687030 hasConcept C2777688143 @default.
• W4308687030 hasConcept C2779234561 @default.
• W4308687030 hasConcept C2779245376 @default.
• W4308687030 hasConcept C2779473830 @default.

• next